Back to Home

TECARTUS® is the first and only FDA-approved CAR T-cell therapy for adults (18+ years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL)1,3,4

TECARTUS was studied in an open-label, single-arm, multicenter trial (ZUMA-3) that evaluated the efficacy and safety of TECARTUS in adult patients with relapsed or refractory B-cell precursor ALL. In ZUMA-3, 54 patients were treated with TECARTUS and were evaluated for efficacy.1

The primary endpoint was overall complete remission rate (OCR) [OCR=complete remission + complete remission with incomplete hematologic recovery]. The efficacy of TECARTUS was established on the basis of complete remission (CR) within 3 months after infusion and the duration of CR (DOCR). Selected secondary endpoints included DOR, allo-SCT rate, and safety.1,4

65%

Overall complete
remission (n=35/54)1

52%

Complete remission
(n=28/54)1

13.6

months mDOR
(median follow-up:
12.3 months)1

Safety analysis for TECARTUS1

Cytokine release syndrome (CRS):

  • CRS occurred in 92% of patients receiving TECARTUS (n=72/78)
  • 26% of patients experienced Grade ≥3 CRS

Neurological toxicities:

  • Neurological events occurred in 87% of patients receiving TECARTUS (n=68/78)
  • 35% of patients experienced Grade ≥3 neurological events

Join us for a live National Broadcast program where disease experts will be discussing the new TECARTUS indication

OCTOBER 2021
THURS21
TUES26
10:00 AM PT / 1:00 PM ET
12:00 PM PT / 3:00 PM ET
3:00 PM PT / 6:00 PM ET
Treatment Center

Find a TECARTUS Authorized Treatment Center for your patients

TECARTUS can only be administered at an Authorized Treatment Center (ATC).
ATCs are independently owned and operated. Kite does not endorse any ATCs.

Contact a TECARTUS® Rep

Contact a TECARTUS Representative

Have questions or need additional information about TECARTUS?
Please complete the form below and a Representative will contact you.

Kite Konnect® logo

Dedicated support throughout the treatment process

Kite Konnect® can help with finding an Authorized Treatment Center and
provide information about the support resources that may be available to you.

1-844-454-KITE [5483], Monday–Friday, 5 AM–6 PM PT.

Authorized Treatment Centers listed are independent facilities certified to dispense Kite CAR T therapies. Choice of an Authorized Treatment Center is within the sole discretion of the physician and patient. Kite does not endorse any individual treatment sites.

Resources may include referrals to independent third-party nonprofit patient assistance programs. These programs are not operated or controlled by Kite. Nonprofit patient assistance program eligibility requirements may vary and are established solely by each independent organization. Kite makes no guarantee with respect to reimbursement or copay assistance for any item or service.

Cell therapy patient programs are for eligible prescribed patients.

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; CAR=chimeric antigen receptor; CR=complete remission; DOCR=duration of complete remission; DOR=duration of response; FDA=Food and Drug Administration; mDOR=median duration of remission; OCR=overall complete remission; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. U.S. FDA approves Kite’s Tecartus® as the first and only CAR T for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. News release. Kite, a Gilead Company; October 1, 2021. Accessed October 1, 2021. https://www.businesswire.com/news/home/20211001005719/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%C2%AE-as-the-First-and-Only-Car-T-for-Adults-With-Relapsed-or-Refractory-B-cell-Acute-Lymphoblastic-Leukemia 3. KYMRIAH® (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2020. 4. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. Published online June 4, 2021. doi:10.1016/S0140-6736(21)01222-8